将毒性与治疗效果分离，是当前皮肤免疫相关不良反应与免疫检查点抑制剂治疗领域研究的基础。通过大规模的、有力的人群水平研究、机构队列数据和细胞水平数据，我们可以理解毒性、肿瘤反应和耐药性的驱动因素。通过共识病定义的应用，提高诊断的特异性，有助于改善临床护理和研究方法。皮肤免疫相关不良反应与提高生存率相关，其治疗必须保持免疫抑制、免疫检查点抑制剂治疗的抗肿瘤效果和生活质量之间的微妙平衡。对于患有不良事件的癌症患者，多学科护理对于优化临床和转化研究结果至关重要，因此皮肤科医生是推动皮肤不良事件研究的关键人物。© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Uncoupling toxicity from therapeutic effect lies at the foundation of the current state of the field of cutaneous immune-related adverse events to immune checkpoint inhibitor therapy. This will be achieved through understanding the drivers of toxicity, tumor response, and resistance via large, well-powered population-level studies, institutional cohort data, and cellular-level data. Increasing diagnostic specificity through the application of consensus disease definitions has the power to improve clinical care and each approach to research. Cutaneous immune-related adverse events are associated with increased survival, and their treatment must invoke the maintenance of a delicate balance between immunosuppression, anti-tumor effect of immune checkpoint inhibitor therapy, and quality of life. The multidisciplinary care of cancer patients with adverse events is critical to optimizing clinical and translational research outcomes and, as such, dermatologists are vital to moving the study of cutaneous adverse events forward.© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.